Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Karsh, Lawrence I
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer Data from CELLO-1 trial for CRPC at SUO 2022 Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022 Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021 Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021	Terminated	1/2	102	Europe, US	Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi	Epizyme, Inc.	Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer	11/24	11/24
Karsh, Larry
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer	Recruiting	N/A	650	US	ADXBLADDER	Arquer Diagnostics Ltd	Bladder Cancer	01/23	04/23
Lightsey, Kathleen
NCT04232696: Neuspera's Implantable Sacral Nerve Stimulation System in Patients with Symptoms of Urinary Urgency Incontinence (UUI)	Active, not recruiting	N/A	242	Europe, US	Neuspera Implantable Sacral Nerve Stimulation System	Neuspera Medical, Inc.	Urinary Urgency Incontinence	07/24	12/26